This newly identified, potent GRP78 inhibitor exhibits preclinical efficacy in a pancreatic cancer xenograft model with no toxicity to normal tissues, as a monotherapy or in combinative therapy (25). This evidence concerns the gene HSPA5 and pancreatic neoplasm.